Ovarian cancer is often caught late, with only 35% of patients surviving for 10 years or more in England. One doctor is ...

But I firmly believe we can also help the many thousands more who don’t have this genetic risk – by carrying out surgery to remove the fallopian tubes in women already earmarked for other ...

More women chose to have their tubes tied after Roe v. Wade was overturned in 2022, a new study shows, and the biggest ...

Human papillomavirus (HPV) and hyperactivated YAP1 form a YAP1-HPV oncogenic alliance to drive the malignant transformation ...

Ovarian cancer is a type of cancer that impacts the female reproductive system. The risk of developing ovarian cancer in a woman's lifetime is 1 in 87, according to the American Cancer Society (ACS).

Pamiparib (Baihuize) is an anti-neoplastic agent. It is formulated as capsules for oral route of administration. Baihuize is indicated for the treatment of patients with germline BRCA ...

In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die ...

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Fallopian Tube Cancer.

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Rucaparib (Rubraca) is available on the NHS. It is a possible maintenance treatment for relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has ...

There is a simple discount patient access scheme for rucaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...